Study Evaluating the Etiology of Intra-Abdominal Infections

Back to Search
Print
Bookmark Trial

NCT00244088

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Intra-abdominal Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- A case will be defined as an intra-abdominal abscess or peritoneal fluid culture that will be positive for enterococcus or an enterococcal bacteriemia in association with an intra-abdominal source of infection.

- A control will be defined as a culture-positive intra-abdominal infection or bacteriemia due to an intraabdominal focus where enterococci have not been isolated.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


-

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Intra-abdominal InfectionA Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
NCT01721408
  1. Anqing, Anhui
  2. Xicheng District, Beijing
  3. Xiamen, Fujian
  4. Zhangzhou, Fujian
  5. Guangzhou, Guangdong
  6. GuangZhou, Guangdong
  7. Shantou, Guangdong
  8. Shenzhen, Guangdong
  9. Guilin, Guangxi
  10. Haikou, Hainan
  11. Haikou, Hainan
  12. Sanya, Hainan
  13. Wuhan, Hubei
  14. Wuhan, Hubei
  15. Wuhan, Hubei
  16. Changsha, Hunan
  17. Changsha, Hunan
  18. Changsha, Hunan
  19. Baotou, Inner Mongolia
  20. Jiangyin, Jiangsu
  21. Suzhou, Jiangsu
  22. Suzhou, Jiangsu
  23. Yangzhou, Jiangsu
  24. Changchun, Jilin
  25. Changchun, Jilin
  26. Changchun, Jilin
  27. Xining, Qinghai
  28. Bin Zhou, Shandong
  29. Shanghai, Shanghai
  30. Chengdu, Sichuan
  31. Chengdu, Sichuan
  32. Kunming, Yunnan
  33. Hangzhou, Zhejiang
  34. Linhai, Zhejiang
  35. Lishui, Zhejiang
  36. Wenzhou, Zhejiang
  37. Beijing,
  38. Beijing,
  39. Beijing,
  40. Beijing,
  41. Beijing,
  42. Shanghai,
  43. Shanghai,
  44. Shanghai,
  45. Tianjin,
  46. Tianjin,
  47. Tianjin,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Intra-abdominal InfectionStudy Evaluating the Etiology of Intra-Abdominal Infections
NCT00244088
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Study Evaluating the Etiology of Intra-Abdominal Infections
Official Title Study of the Etiology of Intra-Abdominal Infections
Brief Summary The aim of this study is to define the etiology of intra-abdominal infections, to study the role of Enterococcus spp and Pseudomonas aeruginosa in these infections and to clarify the need for specific enterococcal antimicrobial coverage.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case Control
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
Intra-abdominal fluid
Sampling Method Non-Probability Sample
Study Population Surgery units
Condition Intra-abdominal Infection
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Enrollment
 (submitted: October 21, 2005)		340
Original Enrollment Same as current
Actual Study Completion Date December 2004
Actual Primary Completion Date December 2004   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • A case will be defined as an intra-abdominal abscess or peritoneal fluid culture that will be positive for enterococcus or an enterococcal bacteriemia in association with an intra-abdominal source of infection.
  • A control will be defined as a culture-positive intra-abdominal infection or bacteriemia due to an intraabdominal focus where enterococci have not been isolated.

Exclusion Criteria:

-

Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT00244088
Other Study ID Numbers 101316
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Principal Investigator:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date August 2009